Coronary Artery Disease (CAD)

November 06, 2022

The late-breaking findings suggest the potential prognostic benefit of highly purified EPA in patients with chronic CAD with a low EPA/AA ratio.

May 13, 2022

Announced on May 13, the Onyx Frontier DES carries the same clinical indications as Medtronic's Resolute Onyx DES and will be available in 2.0 mm sizes as well as 4.50-5.00 mm sizes that can be expanded to 6.00 mm.

April 29, 2022

A panel of expert cardiologists share their concluding thoughts on management of polyvascular disease in clinical practice.

April 29, 2022

Cardiologists share unmet needs and emerging approaches to management of patients with polyvascular disease.

April 29, 2022

Manesh Patel, MD, reviews VOYAGER trial data and expert cardiologists share where they use DPI [dual pathway inhibition] in their practices.

April 29, 2022

Expert cardiologists discuss data from COMPASS trial and the role of rivaroxaban and low-dose aspirin in treatment of patients with CAD and PAD.

April 29, 2022

Sahil Parikh, MD, shares how lack of access to or awareness of DPI [dual pathway inhibition] causes many practices and health care providers to face a challenge in treating CAD [coronary artery disease].

April 29, 2022

Drs Patel and Bhatt discuss importance of correct dosing of direct oral anticoagulants in treatment of cardiovascular diseases.

April 29, 2022

Expert cardiologists provide an overview of dual pathway inhibition, modulation of thrombotic risk and treatment of CAD.

April 29, 2022

Dr Amy Pollak shares her thoughts on risk-benefit analysis when evaluating patients with high thrombotic/bleeding risk and treatment selection.